List/Grid Tag Archives: relapse
Discussing relapse treatments in the UK
Navigating a path through relapsed neuroblastoma is a challenge for parents regardless of geography. However, treatment following relapse is generally determined, at least in the first instance, by locally available options and prevailing attitudes which differ between countries, institutions, and even individual oncologists.
In 2011 Gesellschaft für Pädiatrische Onkologie und Hämatologie (GPOH), ...
Tübingen 2012 Neuroblastoma Symposium: from bench to bedside
Sincere appreciation is extended to NB Alliance UK for inviting me to attend this meeting and providing the travel funds.
This was the fourth meeting in a series on pediatric solid tumors and the first time the focus was on neuroblastoma. It was hosted at the Children’s Hospital (Kinderklinik) in the beautiful old city of Tübingen, which is home to the top ranked German University founded in ...
Hu3F8 is now a reality at Memorial-Sloan Kettering
The Story of the Band of Parents and humanized 3F8
by Caryn Franca and Shirley Staples
It was summer of 2007. A group of parents had asked Dr. Nai-Kong Cheung to meet and update them on new treatments for neuroblastoma at Memorial Sloan-Kettering Cancer Center. Most had children with relapsed neuroblastoma; all knew the terrible odds. Dr. Cheung, head of the neuroblastoma program at MSKCC, ...
Pilot Study of Zoledronic Acid and Interleukin-2 for Refractory Pediatric Neuroblastoma
New phase I trial opening soon at University of Alabama, Birmingham
This trial will enroll 6 patients at 2 dose levels for IL2 given with fixed dose of zoledronic acid. Zoledronic acid will be given IV once every 3 weeks, and daily subcutaneous IL2 given weekdays for 2 weeks.
Patients must have evidence of disease and have not received prior antibody therapy with IL2.
See NIH listing for rationale:
To ...
Update on oncolytic virus trials for neuroblastoma
Four oncolytic virus trials open at Cincinnati Children’s for pediatric solid tumors
Dr Tim Cripe provided a very helpful comparison chart for the oncolytic virus trials currently open at Cincinnati Children’s, and permission to post it. To open a PDF of the chart, click on this link:
Viral study comparison (PDF document)
The chart lists the similarities and differences ...
New antibody trials in 2011
Antibodies for relapsed neuroblastoma
Given that recent studies such as COG-3973 [1] and others reveal that half or more of all children with high-risk neuroblastoma are refractory to induction or relapse, and that the majority worldwide never received antibodies as part of frontline treatment, there is currently a significant demand for access to antibody treatment after relapse.
Currently, the only ...
Antibodies and other bits
Big antibody news
The “third generation” humanized anti-GD2 antibody with protein fusion of IL2 to the antibody has completed Phase I and II clinical trials for melanoma and neuroblastoma, and is now ready for use in Phase III clinical trials. The license for hu14.18-IL2 was just acquired by a small biotech in Vienna called Apeiron. The license was acquired from Merck.
Apeiron’s press ...
Rational relapse therapy for neuroblastoma
Many therapies, robust rationale needed
For years I have (obsessively) tracked clinical trials and therapies available to children with relapsed and refractory neuroblastoma, driven by hope that curing relapsed NB is possible. Since there are many therapies for “unspecified solid tumors” as well as specifically for neuroblastoma, the resulting variety of trials is quite astounding.
I started ...
Status on oncolytic virus therapies for pediatric solid tumors
A review of a new therapy for neuroblastoma
Significant and accelerating progress is underway in the oncolytic virus arena. In the past decade numerous clinical trials using several different oncolytic viruses against adult cancers have been completed and more are underway. Many trials have shown anti-tumor activity in various adult tumors. A major milestone was reached this year with three oncolytic ...
New vaccine trial for relapsed neuroblastoma
Trial open at Penn State Hershey Medical Center
A Phase I Trial Combining Decitabine, IFN-gamma, and Vaccine Therapy for Patients With Neuroblastoma
The phase I trial will enroll 15 children ages 2 months to 17 years who have relapsed neuroblastoma.
The stated purpose:
This treatment study for relapsed high-risk neuroblastoma involves an autologous cancer testis (CT) antigen specific dendritic cell ...
